SureTrader Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, okaly
Search This Board:
Last Post: 11/26/2015 1:29:41 PM - Followers: 322 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.  Webcast from Cowen Healthcare Conference 03/03/14  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW 
Blog Update from CEO B. Culley 12/12/13  NEW  Data From Proof of Concept Study in Heart Failure 

2015 Biotech Conference Presentation Slides: January 12th 2015.

A service of the U.S. National Institutes of Health


  • Make bi


Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc. Identifier:
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
Further study details as provided by Mast Therapeutics, Inc.:
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline


Please refer to this study by its identifier: NCT01737814

Contact: Mast Therapeutics Call Center 1-888-965-1238  

Responsible Party: Mast Therapeutics, Inc. Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on July 25, 2013





MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.


2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing

Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14

2015 Event Schedule

Initiate dosing Phase2a study in AIR001 Q1 '15.  INITIATED 2/4/15

Nonclinical Study EMBOLIC STROKE Data Q1 '15:  POSITIVE DATA RELEASED 2/11/15

Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15

Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15

EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15 INITIATED 5/26/15 

Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15

Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15



EPIC Top Line Data Q1 2016


Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug


Schedule 13D and 13G filings submitted since 09/30/14

  Filing Company Date of
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 12/31/14 4,774,434 4,774,434
  BVF Inc. 3/31/15 7,241,600 7,241,600!
SC 13G FRANKLIN RESOURCES INC 02/04/15 11,946,100 11,946,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 3,382,483    
13F Proquest Associates                                                                                                                                                                                                      MSTX.                        2,551,851




Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries

Investor Relations Contact

Business Development Contact

Careers Contact




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MSTX News: Mast Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference 11/24/2015 08:00:00 AM
MSTX News: Vepoloxamer Data Selected For Presentation At 57th Annual American Society Of Hematology (ASH) Meeting 11/16/2015 08:00:00 AM
MSTX News: Quarterly Report (10-q) 11/12/2015 05:43:49 PM
MSTX News: Current Report Filing (8-k) 11/12/2015 04:08:14 PM
MSTX News: Mast Therapeutics Reports Third Quarter 2015 Financial Results 11/12/2015 04:05:00 PM
#13472  Sticky Note MSTX, It appears there are so many Bx3 10/27/15 03:37:09 AM
#13666   Finally, on the same page. Happy Thanksgiving to Bx3 11/26/15 01:29:41 PM
#13665   Some things in life more important than the pray 11/26/15 09:16:42 AM
#13664   Pray, Where do you come up with this Bx3 11/25/15 07:45:22 PM
#13663   Thank Bx3, you really know how to pray 11/25/15 07:10:18 PM
#13662   MSTX enters pincher status. Boogie time. BooDog 11/25/15 03:01:44 PM
#13661   Valid and significant, for the new to MSTX. Bx3 11/25/15 01:56:19 PM
#13660   I will give a couple of reasons why Bx3 11/24/15 06:56:59 PM
#13659   Interesting how you twist questions and refuse to pray 11/24/15 12:54:50 PM
#13658   Always timely. If new to MSTX, go Bx3 11/24/15 10:48:09 AM
#13657   Pray, In the first place, doesn't he own Bx3 11/24/15 12:50:47 AM
#13656   Give me a break bro .... pray 11/23/15 10:26:57 PM
#13654   Review of significant posts: Go back to this Bx3 11/23/15 10:10:52 PM
#13653   And it is now being delisted by nasdaq? wodehouse 11/23/15 05:45:23 PM
#13652   KBIO got a new CEO. [ My understanding; Bx3 11/23/15 05:33:46 PM
#13651   Not negative, there was a question asked and pray 11/23/15 10:19:20 AM
#13650   Pray , Tell;;;;; For exactly what Bx3 11/21/15 11:33:26 PM
#13649   You are correct; I desire success at MSTX pray 11/21/15 10:52:56 AM
#13648   Needless to say, we are both concerned about Bx3 11/20/15 10:21:19 PM
#13647   You made my point. While MSTX CEO lives pray 11/20/15 08:41:21 PM
#13646   Pray, i know that you are very interested Bx3 11/20/15 04:22:41 PM
#13644   Added back in .39's Entering pincher status. Right BooDog 11/20/15 12:13:42 PM
#13643   Interesting …. What if a bio company pray 11/20/15 10:11:15 AM
#13642   Lux 1, totally agree. Years ago, Rheoth ( Bx3 11/20/15 09:06:14 AM
#13641   a trial of Rheoth 20 years ago showed lux1 11/20/15 03:55:18 AM
#13640   Interesting. Watching a trauma show documentary filmed in Bx3 11/19/15 10:06:10 PM
#13639   i think uptrend will continue tomorrow and next week. Letsgogreen 11/19/15 08:55:16 PM
#13638   Hpefully. wodehouse 11/19/15 12:54:39 PM
#13637   Lux, it is so good to be able Bx3 11/19/15 11:53:59 AM
#13636   When you say "This indicates that the previous pray 11/19/15 11:04:13 AM
#13635   A Harami Cross occurs when the correlating efficient wodehouse 11/19/15 10:53:34 AM
#13634   A Harami Cross? Never seen that before? pray 11/19/15 08:52:05 AM
#13633   knocking out stop losses is one of the BooDog 11/19/15 08:30:03 AM
#13632   Stay Short ...... pray 11/18/15 09:44:10 PM
#13631   * * $MSTX Video Chart 11-18-15 * * ClayTrader 11/18/15 05:03:10 PM
#13630   the good thing is it doesn't matter how okaly 11/18/15 03:36:31 PM
#13629   Yea you are right .... added those two pray 11/18/15 03:32:55 PM
#13628   i think your math is off. okaly 11/18/15 02:38:46 PM
#13627   With all those shares at one point the pray 11/18/15 01:45:40 PM
#13626   Not ballsy but pure "stupidity" for ever buying pray 11/18/15 01:19:47 PM
#13625   I am shorting this one weekly. RNsidersbuying 11/18/15 12:15:49 PM
#13624   New 52 week low. GMONEY4 11/18/15 10:58:09 AM
#13623   Kinda hard if other institutions selling out. pray 11/18/15 10:58:01 AM
#13622   Get the lowest avg you can and hold. Bread Man 11/18/15 10:52:37 AM
#13620   Over 2.5 million shares traded before 11:00 am. pray 11/18/15 10:45:38 AM
#13619   Culley says you're welcome, here's some more at okaly 11/18/15 10:42:55 AM
#13618   As I predicted months ago, this experiment will okaly 11/18/15 10:38:24 AM
#13617   Another New Record Low! pray 11/18/15 10:28:25 AM
#13616   I would respectfully disagree. Yes I consider myself pray 11/18/15 10:09:03 AM
#13615   Point being, BB sees GOOD reason to be Bx3 11/18/15 08:43:08 AM
#13614   Yes but 11 other institutions either downscaled or pray 11/17/15 08:54:35 PM